Whatever the FDA decides on aducanumab, Alzheimer's research is finally, mostly, kind of moving beyond the amyloid hypothesis

Jason Mast

Editor

When Biogen announced in March 2019 that their vaunted Alzheimer’s drug aducanumab failed two large late-studies, Rachael Neve wondered whether the field might finally …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Whatever the FDA decides on aducanumab, Alzheimer's research is finally, mostly, kind of moving beyond the amyloid hypothesis

Jason Mast

Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

What­ev­er the FDA de­cides on ad­u­canum­ab, Alzheimer's re­search is fi­nal­ly, most­ly, kind of mov­ing be­yond the amy­loid hy­poth­e­sis

Jason Mast

Editor

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Whatever the FDA decides on aducanumab, Alzheimer's research is finally, mostly, kind of moving beyond the amyloid hypothesis

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?